The effect of dialysate glucose on phagocyte superoxide generation in CAPD patients

Peritoneal Dialysis International

Volumn 18, Issue 1, 1998, Pages 52-59

  Kashem, Abul ^a   Nomoto, Yasuo ^a   Tanabe, Ryoji ^a   Nishina, Makoto ^a   Endoh, Haruko ^a   Nakajima, Keiko ^a   Endoh, Masayuki ^a   Sakai, Hideto ^a   Nakazawa, Hiroe ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

CAPD patients; Dialysate glucose; Phagocyte superoxide generation

Indexed keywords

AMINO ACID; GLUCOSE; OSMOTIC AGENT; PERITONEAL DIALYSIS FLUID; PHORBOL 13 ACETATE 12 MYRISTATE; SUPEROXIDE;

ADULT; AEROBIC METABOLISM; ARTICLE; CELL METABOLISM; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HEXOSE MONOPHOSPHATE SHUNT; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; LEUKOCYTE; MALE; MONOCYTE; NEUTROPHIL; OSMOLALITY; PERITONEUM CELL; PH; PHAGOCYTE; PRIORITY JOURNAL; TIME;

EID: 0031898526     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089801800106     Document Type: Article

References (32)

1. Rist RJ, Jones GE, Naftalin RJ. Effects of macrophage colony-stimulating factor and phorbol myristate acetate on 2-D-deoxyglucose transport and Superoxide production in rat peritoneal macrophages. Biochem J 1991; 278:119-28.
2. Breborowicz A. Free radicals in peritoneal dialysis: agents of damage? Perit Dial Int 1992; 12:194-8.
3. Simon RH, Scoggin CH, Patterson D. Hydrogen peroxide causes fatal injury to human fibroblasts exposed to oxygen radicals. J Biol Chem 1981; 256:7181-6.
4. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. J Clin Invest 1978; 61:1161-7.
5. Breborowicz A, Witowski J, Wieczorowska K, Martis L, Serkes KD, Oreopoulos DG. Toxicity of free radicals to mesothelial cells and peritoneal membrane.Nephron 1993; 65:62-6.
6. Alobaidi HM, Coles GA, Davies M, Lloyd D. Host defense in continuous ambulatory peritoneal dialysis: The effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1986; 1:16-21.
7. Topley N, Alobaidi HM, Davies M, Coles GA, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988; 34:404-11.
8. Young GA, Hobson SM, Young SM, Young JB, Hildreth B, Gibson J, et al. Adverse effects of hypertonic dialysis fluid during CAPD. Lancet 1983; ii(8364):1421.
9. Ramos JM, Heaton A, McGurk JG, Ward MK, Kerr DNS. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983; 35:20-3.
10. Gallimore B, Gagnon RF, Richards GK. Response of chronic renal failure mice to peritoneal Staphylococcus epidermidis challenge: impact of repeated peritoneal instillation of dialysis solution. Am J Kidney Dis 1989; 14:184-95.
11. Kashem A, Endoh M, Nomoto Y, Sakai H, Nakazawa H. FcαR expression on polymorphonuclear leukocyte and Superoxide generation in IgA nephropathy. Kidney Int 1994; 45:868-75.
12. Kashem A, Endoh M, Nomoto Y, Sakai H, Nakazawa H. Monocyte superoxide generation and its IgA-receptor in IgA nephropathy. Clin Nephrol 1996; 45:1-9.
13. Pronai L, Nakazawa H, Ichimori K, Saigusa Y, Ohkubo T, Hiramatsu K, et al. Time course of superoxide generation by leukocytes. The MCLA chemiluminescence system. Inflammation 1992; 16:437-50.
14. Babior BM. Oxidants from phagocytes: agents of defense and destruction. Blood 1984; 64:959-66.
15. Duwe AK, Vas SI, Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bacterial activity in vitro. Infect Immun 1981; 33:130-5.
16. Ing BL, Gupta DK, Nawab ZM, Zhou FQ, Rahman MA, Daugirdas JT. Suppression of neutrophil superoxide production by conventional peritoneal dialysis solutions. Int J Artif Organs 1988; 11:351-4.
17. Jörres A, Jörres D, Gahl GM, Kessel M, Muller C, Kottgen E, et al. Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate. Nephron 1991; 58:276-82.
18. De Fijter CWH, Verbrugh HA, Oe LP, Peters EDJ, Van Der Meulen J, Donker AJM, et al. Peritoneal defense in continuous ambulatory versus continuous cyclic peritoneal dialysis. Kidney Int 1992; 42:947-50.
19. Liberek T, Topley N, Jörres A, Petersen MM, Coles GA, Gahl GM, et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65:260-5.
20. Topley N, Mackenzie R, Petersen MM, Beavis MJ, Williams D, Thomas N, et al. In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991; 6:574-81.
21. Zhou FQ, Manahan FJ, Yu AW, Rahaman MA, Nawab ZM, Fisher KA, et al. Effects of hypertonic peritoneal dialysis solutions on neutrophil superoxide production. Artif Organs 1990; 14:410-12.
22. Liberek T, Topley N, Jörres A, Coles GA, Gahl GM, Williams JD. Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3:1508-15.
23. Kitagawa S, Takaku F, Sakamoto S. A comparison of the superoxide-releasing response in human polymorphonuclear leukocytes and monocytes. J Immunol 1980; 125:359-64.
24. Sagone AL, King GW, Metz EM. A comparison of the metabolic response to phagocytosis in human granulocytes and monocytes. J Clin Invest 1976; 57:1352-8.
25. Rhee MS, McGoldrick MD, Meuwissen HJ. Serum factor from patients with chronic renal failure enhances polymorphonuclear leukocyte oxidative metabolism. Nephron 1986; 42:6-13.
26. Davies KJA. Protein damage and degradation by oxygen radicals. J Biol Chem 1987; 262:9895-901.
27. 2-microglobulin treated with oxygen-derived radicals. Biochem J 1991; 277:175-82.
28. 2-microglobulin: A new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986; 30:385-90.
29. Benz RL, Siegfried JW, Tehan BP. Carpal tunnel syndrome in dialysis patients: comparison between continuous ambulatory peritoneal dialysis and hemodialysis population. Am J Kidney Dis 1988; 11:473-6.
30. Lamb EJ, Cattell WR, Dawnay AB. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995; 47:1768-74.
31. Oren A, Wu G, Anderson GH, Marliss E, Khanna R, Pettit J, et al. Effective use of amino acid dialysate over four weeks in CAPD patients. ASAIO Trans 1983; 29:604-10.
32. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linarif F. CAPD with an amino acid dialysis solution: a long-term cross-over study.Kidney Int 1989; 35:1189-94.